Shots:
Metsera announced entering into an amended merger agreement with Pfizer to acquire Metsera for up to $86.25 per share, including $65.60 in cash and a contingent value right of up to $20.65
Metsera’s Board of Directors noted that the U.S. Federal Trade Commission had raised potential antitrust concerns regarding Novo Nordisk’s proposed structure
After…
